Special 3/2012

  • Antibodies 2.0 – unlocking new markets

    In this special issue:

    • Biotech partnering and the other IP
    • Dealmaking in 2012
    • Enhancing ADCC
    • Effectively upscaling bioprocesses
    • Meeting scientificand regulatory needs
    • Armed antibodies to fight cancer

Volume 2014

Volume 2013

Volume 2012

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/magazine/spezial/2012/3/pos/1.html?cHash=8305edff5982cb307c5ea48106acb36a&sort=desc

Kurszettel

Alle Kurse

TOP

  • SANTHERA74.95 CHF10.30%
  • BIOTEST80.50 EUR6.83%
  • WILEX2.22 EUR5.71%

FLOP

  • 4SC1.20 EUR-6.25%
  • VITA 343.78 EUR-2.83%
  • EPIGENOMICS3.12 EUR-2.50%

TOP

  • WILEX2.22 EUR177.5%
  • MAGFORCE6.50 EUR17.1%
  • SANTHERA74.95 CHF10.2%

FLOP

  • VITA 343.78 EUR-24.6%
  • MOLOGEN7.80 EUR-19.3%
  • PAION2.40 EUR-17.2%

TOP

  • SANTHERA74.95 CHF3647.5%
  • CO.DON2.50 EUR212.5%
  • PAION2.40 EUR182.4%

FLOP

  • CYTOS0.27 CHF-93.3%
  • MEDIGENE4.60 EUR-67.7%
  • THERAMETRICS0.08 CHF-46.7%

No liability assumed, Date: 19.08.2014